Please login to the form below

Not currently logged in
Email:
Password:

T-DM1

This page shows the latest T-DM1 news and features for those working in and with pharma, biotech and healthcare.

Immunotherapy and future directions in oncology

Immunotherapy and future directions in oncology

Those dendritic cells can activate cytotoxic T-cells which, after replicating, track and eradicate cancer cells. ... Kadcyla (trastuzumab emtansine, Genentech of Roche) targets HER2 receptors present in breast cancer and delivers an anti-microtubule

Latest news

  • EU backs Roche’s Kadcyla in breast cancer EU backs Roche’s Kadcyla in breast cancer

    Expectations are high for the Kadcyla, which is an antibody-drug conjugate (ADC) that combines the monoclonal antibody in Herceptin with ImmunoGen's DM1, a cytotoxic payload designed to boost its

  • Roche's Herceptin follow-up cleared in US Roche's Herceptin follow-up cleared in US

    FDA approval for Kadcyla (formerly T-DM1) in breast cancer. Roche won approval in the US late last week for Kadcyla, its much-anticipated follow-up to breast cancer blockbuster Herceptin. ... The FDA has given the go-ahead to Kadcyla, formerly known as

  • Product updates from Japan

    pylori", according to the partners. Chugai Pharmaceutical has filed for approval of trastuzumab emtansine (T-DM1) - originally developed by Roche/Genentech as a follow-up to their Herceptin (trastuzumab) blockbuster - for ... Chugai has commercialisation

  • Roche delivers solid sales gain in 2012 Roche delivers solid sales gain in 2012

    Perjeta has been tipped as a future blockbuster, as has Herceptin follow-up trastuzumab emtansine ( T-DM1), which is filed in the US and Europe and expected to be on the

  • Genentech cancer drug delayed

    Genentech is seeking approval for trastuzumab-DM1 (T-DM1) for use in patients with advanced HER2-positive breast cancer who have previously received multiple HER2-targeted medicines and chemotherapies. ... T-DM1 links ImmunoGen's tumour-activated prodrug

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
TRIDUCIVE

Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...

Latest intelligence

Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
6 critical success factors for flawless execution of a rapid first commercial launch
Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....